Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CES1 | P23141 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8531622 | 0.85 | MAPT (0.52) | KMT2AMAPTMAPK1MEN1TDP1 | |
| SCHEMBL3242580 | 0.84 | MAPT (0.56) | KMT2AMAPTMAPK1MEN1TDP1 | |
| SCHEMBL9733475 | 0.83 | HSD17B3 (0.52) | MAPK1TDP1KDM4EALDH1A1PTPN1 | |
| SCHEMBL10636565 | 0.83 | KMT2A (0.50) | KMT2AMAPTMAPK1MEN1TDP1 | |
| SCHEMBL23064499 | 0.83 | MAPT (0.50) | KMT2AMAPTMAPK1MEN1TDP1 | |
| SCHEMBL95591 | 0.83 | KMT2A (0.54) | KMT2AMAPTMAPK1MEN1TDP1 | |
| SCHEMBL95590 | 0.83 | MAPT (0.54) | KMT2AMAPTMAPK1MEN1TDP1 | |
| SCHEMBL3382150 | 0.82 | PPARA (0.43) | KMT2AMAPTMAPK1MEN1TDP1 | |
| SCHEMBL10594877 | 0.82 | GSK3B (0.53) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL30697987 | 0.82 | KMT2A (0.48) | KMT2AMAPTMAPK1MEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-20240376104-A1 | Bcl-2 Inhibitors | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| US-12077536-B2 | BCL-2 inhibitors | BEIGENE, LTD. (KY) | 2024-09-03 | — | — | US | disclosed |
| CN-117683029-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117430601-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-112437772-B | Bcl-2 inhibitors | 百济神州有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
| US-11420968-B2 | Bcl-2 inhibitors | BEIGENE, LTD. (KY) | 2022-08-23 | — | — | US | disclosed |
| EP-3788042-A1 | BCL-2 INHIBITORS | BeiGene, Ltd. (KY) | 2021-03-10 | — | — | EP | disclosed |
| EP-1404657-A1 | PYRIDAZINONE | Bayer HealthCare AG (DE) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003089421-A1 | ANTIVIRAL LACTONE-UREAS | BAYER HEALTHCARE AG (DE) | 2003-10-30 | — | — | WO | disclosed |
| US-20030114453-A1 | Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-06-19 | — | — | US | disclosed |
| WO-2003002541-A1 | PYRIDAZINONE | BAYER HEALTHCARE AG (DE) | 2003-01-09 | — | — | WO | disclosed |
| CN-1368972-A | Non-steroidal IL-5 inhibitors, process for their preparation and pharmaceutical compositions containing them | JANSSEN PHARMACEUTICA NV (BE) | 2002-09-11 | — | — | CN | disclosed |
| EP-1206471-A1 | INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001010866-A1 | INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-02-15 | — | — | WO | disclosed |
| EP-0115133-B1 | SPIRO-3-HETERO-AZOLONES FOR TREATMENT OF DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1989-01-25 | — | — | EP | disclosed |
| US-4556670-A | Spiro-3-hetero-azolones for treatment of diabetic complications | PFIZER INC. (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0115133-A1 | Spiro-3-hetero-azolones for treatment of diabetic complications | PFIZER INC. (US) | 1984-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | KMT2A 2464/4885MAPT 2900/4885MAPK1 1202/4885 |
| US-11420968-B2 | Bcl-2 inhibitors | BCL2, BCL2L1, BCL2L2 | KMT2A 2464/4885MAPT 2900/4885MAPK1 1202/4885 |
| US-12077536-B2 | BCL-2 inhibitors | BCL2, BCL2L1, BCL2L2 | KMT2A 2464/4885MAPT 2900/4885MAPK1 1202/4885 |
| US-20240376104-A1 | Bcl-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | KMT2A 2464/4885MAPT 2900/4885MAPK1 1202/4885 |
| US-20030114453-A1 | Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | IL5, IL15, IL15RA | KMT2A 3703/4885MAPT 3954/4885MAPK1 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.